Stockreport

Kiniksa Announces Early Evidence of Treatment Response with Mavrilimumab in 6 Patients with Severe COVID-19 Pneumonia and Hyperinflammation

Kiniksa Pharmaceuticals, Ltd. - Class A  (KNSA) 
Last kiniksa pharmaceuticals, ltd. - class a earnings: 8/12 04:02 pm Check Earnings Report
PDF  - All 6 patients treated with mavrilimumab showed resolution of fever and did not progress to mechanical ventilation; follow-on controlled study in Italy planned - - Co [Read more]